000000_Synthonics_ChyloCureBook_Rev031919

What is

ChyloCure is a nutritional supplement company focused on the commercialization of Chylobinoids. Chylobinoids are a proprietary mineral-infused, full-spectrum cannabinoid complex that is rich in CBDa. Chylobinoids provide more consistent dos- ing and greater potency than most products derived from cannabis. They can be easily formu- lated into a variety of products, including creams, lotions, capsules, and edibles. Unlike most hemp-based products, which con- sist primarily of CBD, Chylobinoids consist primarily of cannabidiolic acid (CBDa), the acid form of CBD. Although much research in the space is prelimi- nary, CBDa is reportedly more effective than CBD in the treatment of inflammation, epilepsy, nau- sea, pain, and some neurodegenerative diseases. Moreover, Chylobinoids are designed to bypass the body’s hepatic metabolism—leading to greater absorption of the cannabinoid payload into the bloodstream. We believe that their CBDa-rich na- ture and improved absorption will distinguish Chylobinoids from other hemp-based products. Where did Chylobinoids come from? Chylobinoids, and the process used to produce them, were developed by Synthonics—a company founded to discover and develop metal- coordinated pharmaceuticals. Because Synthonics focuses on the improvement and licensing of FDA- approved products, it is establishing ChyloCure as a separate company that will have the exclusive right to Synthonics’ intellectual property for the produc- tion and sale of cannabis-containing nutraceuticals. Is there a market for Chylobinoids? The market for CBD/CBDa products is large and growing rapidly. It is projected to grow from just under $600 million in 2018 to $22 billion in 2022. We believe that ChyloCure’s unique formulation and technology positions it to benefit from this explosive growth.

How can I get Chylobinoids? We are currently producing Chylobinoid powder, solution, capsules, and creams on a small scale. We have received enthusiastic responses from the us- ers of our solution, capsules, and creams, and we have testimonials endorsing the effectiveness of our Chylobinoid products. Based on these prelimi- nary results, we intend to substantially expand the scope of our Chylobinoid business. We initially intend to sell bulk powder to dis- tributors and retailers, and to white label capsules, creams, lotions, and edibles for wholesalers or re- tail outlets. As our market presence expands, we will explore the establishment of our own brand of products. I’m interested. Now what? To support the launch of ChyloCure and the ex- pansion of its operations, we are offering convertible notes in ChyloCure. The notes will con- vert into equity at the lesser of $10 per share or 80% of the price paid by investors in the next round. This structure allows investors to benefit from an early investment (through the $10.00/share cap) while protecting them against a subsequent down round (through the 20% dis- count). We believe that the note proceeds will allow us to significantly increase our production capacity and to market our product aggressively. The pro- ceeds will go towards acquiring a royalty-free li- cense from Synthonics, securing a manufacturing facility, purchasing larger manufacturing equip- ment, operating expenses, and marketing. Our anticipated exit, which we hope will occur by 2021, is to either offer sale of ChyloCure stock publicly or be purchased.